|
1
|
d'Amore F, Brincker H, Christensen BE,
Thorling K, Pedersen M, Nielsen JL, Sandberg E, Pedersen NT and
Sørensen E: Non-Hodgkin's lymphoma in the elderly. A study of 602
patients aged 70 or older from a Danish population-based registry.
The Danish LYEO-study group. Ann Oncol. 3:379–386. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feugier P, Van Hoof A, Sebban C,
Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E,
Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP
study in the treatment of elderly patients with diffuse large
B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peyrade F, Jardin F, Thieblemont C, Thyss
A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi
O, et al: Attenuated immunochemotherapy regimen (R-miniCHOP) in
elderly patients older than 80 years with diffuse large B-cell
lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol.
12:460–468. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi Y, Miura K, Hojo A, Hatta Y,
Tanaka T, Kurita D, Iriyama N, Kobayashi S and Takeuchi J: Charlson
comorbidity index is an independent prognostic factor among elderly
patients with diffuse large B-cell lymphoma. J Cancer Res Clin
Oncol. 137:1079–1084. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheson BD and Rummel MJ: Bendamustine:
Rebirth of an old drug. J Clin Oncol. 27:1492–1501. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rummel MJ, Niederle N, Maschmeyer G, Banat
GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M,
Balser C, et al: Bendamustine plus rituximab versus CHOP plus
rituximab as first-line treatment for patients with indolent and
mantle-cell lymphomas: An open-label, multicentre, randomised,
phase 3 non-inferiority trial. Lancet. 381:1203–1210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flinn IW, van der Jagt R, Kahl BS, Wood P,
Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M,
et al: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP
in first-line treatment of indolent NHL or MCL: The BRIGHT study.
Blood. 123:2944–2952. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong JY, Yoon DH, Suh C, Kim WS, Kim SJ,
Jo JC, Kim JS, Lee WS, Oh SY, Park Y, et al: Bendamustine plus
rituximab for relapsed or refractory diffuse large B cell lymphoma:
A multicenter retrospective analysis. Ann Hematol. 97:1437–1443.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohmachi K, Niitsu N, Uchida T, Kim SJ,
Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, et al:
Multicenter phase II study of bendamustine plus rituximab in
patients with relapsed or refractory diffuse large B-cell lymphoma.
J Clin Oncol. 31:2103–2109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fields PA and Linch DC: Treatment of the
elderly patient with diffuse large B cell lymphoma. Br J Haematol.
157:159–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balducci L and Extermann M: Management of
cancer in the older person: A practical approach. Oncologist.
5:224–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Extermann M, Aapro M, Bernabei R, Cohen
HJ, Droz JP, Lichtman S, Mor V, Monfardini S, Repetto L, Sørbye L,
et al: Use of comprehensive geriatric assessment in older cancer
patients: Recommendations from the task force on CGA of the
international society of geriatric oncology (SIOG). Crit Rev Oncol
Hematol. 55:241–252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tucci A, Martelli M, Rigacci L, Riccomagno
P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S,
et al: Comprehensive geriatric assessment is an essential tool to
support treatment decisions in elderly patients with diffuse large
B-cell lymphoma: A prospective multicenter evaluation in 173
patients by the lymphoma Italian foundation (FIL). Leuk Lymphoma.
56:921–926. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cazzola M: Introduction to a review
series: the 2016 revision of the WHO classification of tumors of
hematopoietic and lymphoid tissues. Blood. 127:2361–2364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia; Lymphoma Group and Eastern Cooperative Oncology Group, ;
et al: Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano
classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dueck AC, Mendoza TR, Mitchell SA, Reeve
BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM,
O'Mara AM, et al: Validity and reliability of the US national
cancer institute's patient-reported outcomes version of the common
terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol.
1:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martelli M, Ferreri AJ, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Advani RH, Chen H, Habermann TM, Morrison
VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ;
Eastern Cooperative Oncology Group, ; et al: Comparison of
conventional prognostic indices in patients older than 60 years
with diffuse large B-cell lymphoma treated with R-CHOP in the US
intergroup study (ECOG 4494, CALGB 9793): Consideration of age
greater than 70 years in an elderly prognostic index (E-IPI). Br J
Haematol. 151:143–151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pal SK, Katheria V and Hurria A:
Evaluating the older patient with cancer: Understanding frailty and
the geriatric assessment. CA Cancer J Clin. 60:120–132. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kayamori K, Shono K, Onoda M and Yokota A:
Efficacy and tolerability of rituximab and reduced-dose
cyclophosphamide, doxorubicin, vincristine, and prednisolone
therapy for elderly patient with diffuse large B-cell lymphoma.
Hematology. 24:52–59. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Flinn IW, van der Jagt R, Kahl B, Wood P,
Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, et
al: First-line treatment of patients with indolent non-Hodgkin
lymphoma or mantle-cell lymphoma with bendamustine plus rituximab
versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up
study. J Clin Oncol. 37:984–991. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mondello P, Steiner N, Willenbacher W,
Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S and Mian M:
Bendamustine plus rituximab versus R-CHOP as first-line treatment
for patients with follicular lymphoma grade 3A: Evidence from a
multicenter, retrospective study. Oncologist. 23:454–460. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woyach JA, Ruppert AS, Heerema NA, Zhao W,
Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, et
al: Ibrutinib regimens versus chemoimmunotherapy in older patients
with untreated CLL. N Engl J Med. 379:2517–2528. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ribes D, Hachem HEL, Oberic L, Vergez F,
Delas A, Belliere J, Protin C, Kamar N, Ferrandiz I, Tavitian S, et
al: Bendamustine plus rituximab for indolent B-cell lymphoma of
renal significance. Am J Hematol. 93:356–362. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Horn J, Kleber M, Hieke S, Schmitt-Gräff
A, Wäsch R and Engelhardt M: Treatment option of bendamustine in
combination with rituximab in elderly and frail patients with
aggressive B-non-Hodgkin lymphoma: Rational, efficacy, and
tolerance. Ann Hematol. 91:1579–1586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng CL, Liu JH, Chou SC, Yao M, Tang JL
and Tien HF: Retrospective analysis of frontline treatment efficacy
in elderly patients with diffuse large B-cell lymphoma. Eur J
Haematol. 101:28–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Storti S, Spina M, Pesce EA, Salvi F,
Merli M, Ruffini A, Cabras G, Chiappella A, Angelucci E, Fabbri A,
et al: Rituximab plus bendamustine as front-line treatment in frail
elderly (>70 years) patients with diffuse large B-cell
non-Hodgkin lymphoma: A phase II multicenter study of the
Fondazione Italiana Linfomi. Haematologica. 103:1345–1350. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park SI, Grover NS, Olajide O, Asch AS,
Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, et
al: A phase II trial of bendamustine in combination with rituximab
in older patients with previously untreated diffuse large B-cell
lymphoma. Br J Haematol. 175:281–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weidmann E, Neumann A, Fauth F, Atmaca A,
Al-Batran SE, Pauligk C and Jäger E: Phase II study of bendamustine
in combination with rituximab as first-line treatment in patients
80 years or older with aggressive B-cell lymphomas. Ann Oncol.
22:1839–1844. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sehn LH, Herrera AF, Flowers CR, Kamdar
MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M,
et al: Polatuzumab vedotin in relapsed or refractory diffuse large
B-cell lymphoma. J Clin Oncol. 38:155–165. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan XW, Wang HQ, Ban WW, Chang Z, Chen
HZ, Jia L and Liu FT: Novel HDAC inhibitor chidamide synergizes
with rituximab to inhibit diffuse large B-cell lymphoma tumour
growth by upregulating CD20. Cell Death Dis. 11:202020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bojarczuk K, Wienand K, Ryan JA, Chen L,
Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN,
Chapuy B and Shipp MA: Targeted inhibition of PI3Kα/δ is
synergistic with BCL-2 blockade in genetically defined subtypes of
DLBCL. Blood. 133:70–80. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sasi BK, Martines C, Xerxa E, Porro F,
Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzynska B, Stachura J, et
al: Inhibition of SYK or BTK augments venetoclax sensitivity in
SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Leukemia. 33:2416–2428. 2019. View Article : Google Scholar : PubMed/NCBI
|
